Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CTNNB1 | P35222 | 9/20 | 0.54 |
| ▸ | WNT3A | P56704 | 9/20 | 0.54 |
| ▸ | PLOD2 | O00469 | 3/20 | 0.47 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.46 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.43 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31475594 | 1.00 | LMNA (0.56) | LMNAGAACTNNB1WNT3APLOD2 | |
| SCHEMBL2494518 | 0.82 | LMNA (0.56) | LMNAGAACTNNB1WNT3APTGS1 | |
| SCHEMBL8489375 | 0.82 | LMNA (0.56) | LMNAGAACTNNB1WNT3APTGS1 | |
| SCHEMBL30089582 | 0.81 | CTNNB1 (0.75) | LMNAGAACTNNB1WNT3ACNR2 | |
| SCHEMBL1924959 | 0.80 | PTPN1 (0.61) | LMNAGAACTNNB1WNT3APLOD2 | |
| SCHEMBL19858887 | 0.79 | CTNNB1 (0.58) | LMNAGAACTNNB1WNT3APTGS1 | |
| SCHEMBL2073272 | 0.79 | CTNNB1 (0.58) | LMNAGAACTNNB1WNT3APTGS1 | |
| SCHEMBL3549199 | 0.79 | LMNA (0.53) | LMNAGAACTNNB1WNT3AKCNK3 | |
| SCHEMBL8439499 | 0.79 | LMNA (0.53) | LMNAGAACTNNB1WNT3AKCNK3 | |
| SCHEMBL1923885 | 0.79 | ERCC5 (0.59) | LMNAPLOD2PLOD3PLOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214974-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | PSY THERAPEUTICS, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250170101-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT AND MANAGEMENT OF PAIN AND RELATED CONDITIONS | PSY THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-12286421-B2 | Inhibiting monoacylglycerol lipase (MAGL) | PSY THERAPEUTICS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| WO-2025010394-A2 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT AND MANAGEMENT OF INFLAMMATORY CONDITIONS | PSY THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| WO-2025010392-A2 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PSY THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| US-20240308985-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | PSY THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| WO-2023130050-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT AND MANAGEMENT OF PAIN | PSY THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023130043-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT OF ANXIETY | PSY THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-1910307-A1 | PYRAZOLE BASED LXR MODULATORS | Exelixis, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214974-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | MGLL, PNLIP, LIPC | LMNA 1687/4885GAA 78/4885CTNNB1 4046/4885 |
| US-12286421-B2 | Inhibiting monoacylglycerol lipase (MAGL) | MGLL, PNLIP, LIPC | LMNA 1687/4885GAA 78/4885CTNNB1 4046/4885 |
| US-20250170101-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS AND USE THEREOF FOR THE TREATMENT AND MANAGEMENT OF PAIN AND RELATED CONDITIONS | MGLL, PNLIP, LIPA | LMNA 1904/4885GAA 198/4885CTNNB1 2662/4885 |
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | LMNA 1608/4885GAA 2305/4885CTNNB1 2536/4885 |
| US-20240308985-A1 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | MGLL, PNLIP, LIPC | LMNA 1687/4885GAA 78/4885CTNNB1 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.